Dextromethorphan‐bupropion shows efficacy in two depression trials
The Brown University Psychopharmacology Update September 1, 2022 DOI: 10.1002/pu.30912
Summary
AI-generated from the abstractA medication that combines dextromethorphan and bupropion reduced depressive symptoms more effectively than an active comparator and placebo in adults with major depressive disorder, according to two trials. Remission rates with the combination separated from the comparator and placebo by week 2 of treatment in each study. The Phase 2 trial results appeared in the American Journal of Psychiatry, and the Phase 3 trial results appeared in the Journal of Clinical Psychiatry.
Study at a glance
| Characteristics | Randomized controlled trial Peer reviewed |
|---|---|
| Population | Adults with major depressive disorder |
| Key finding | Dextromethorphan-bupropion was more efficacious than an active comparator and placebo in reducing depressive symptoms, with remission rates separating by week 2. |
Abstract
A medication combining dextromethorphan and bupropion was more efficacious than an active comparator and placebo in reducing depressive symptoms in adults with major depressive disorder, a pair of trials has found. Remission rates with dextromethorphan‐bupropion separated from the comparator and placebo by week 2 of treatment in each study, according to researchers. Results of the Phase 2 trial of the medication were published online May 18 in the American Journal of Psychiatry, and results of the Phase 3 trial were published online May 30 in the Journal of Clinical Psychiatry.